

Adverse Uses and Effects of Gemcitabine

Department of Chemistry, Imam Khomeini International University, Iran

Editorial

Gemcitabine is used in different carcinoma. It is used as a first-line therapy alone for pancreatic malignancy and in combination with cisplatin for cholangiocarcinoma and bladder cancer and progressed or metastatic non-small cell lung cancer. It is used as a second-line therapy in combination with carboplatin for ovarian malignancy and in combination with paclitaxel for chemotherapy-resistant metastatic breast cancer. Since its clinical significance and adjustable combination in radiotherapy reformulation is of interest to be given more attention.

In the era of pharmacogenomic and pharmacogenetics has been considered. Since 2014, it is a major factor in the hereditary disease could be helpful in managing drug and individualized therapy of gemcitabine. In addition, apparent variation in the level of protein (SLC29A1, SLC29A2, SLC28A1, and SLC28A3) is used for transport of gemcitabine in the cell lead to variation in response. Also, the quality of the protein has lead to inactivation of adenosine deaminase, adenosine deaminase, and (T5C) and have potential for resistance (RRM1, RRM2, and RRM2B) lead to variation because of the medication. Efficacy has additionally been considered to be the form of ion in pancreatic cancer. However, the decision reaction of gemcitabine. It has been read as a therapy for Kaposi sarcoma, a typical malignancy in individuals with AIDS.

Mohammadreza Khanmohammadi, Department of Chemistry, Imam Khomeini International University, Iran, E-mail: mohammad.k@gmail.com

November 06, 2020;
November 27, 2020

November 20, 2020;

Gemcitabine. J Cancer Diag 4: 2.

© 2020 Mohammadreza Khanmohammadi. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.